GlaxoSmithKline plc / Genmab A/S (HuMax-TAC follow-on)

B-cell malignancies (chronic lymphocytic leukemia, follicular non-Hodgkin lymphoma) and B-cell-mediated autoimmune disease (rheumatoid arthritis)

16K US cases/yr · $2.1B Headline aggregate value of GSK-Genmab ofatumumab agreement (initial license + equity + milestones)

Disease Overview

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the West, a slow-progressing B-cell malignancy driven by accumulation of CD5+/CD20+ mature lymphocytes; double-refractory disease (post-fludarabine/post-alemtuzumab) had no standard of care prior to Arzerra. Follicular NHL is an indolent CD20+ B-cell lymphoma; rheumatoid arthritis is a B-/T-cell-mediated autoimmune joint disease with established anti-CD20 (rituximab) precedent.

Competitive Landscape

When GSK signed the original ofatumumab co-development agreement with Genmab in December 2006 (HuMax-CD20, ~$2.1B headline value including equity, upfront, and oncology+autoimmune milestones; https://www.fiercebiotech.com/biotech/press-release-gsk-and-genmab-sign-2-1b-deal-for-humax-cd20), the anti-CD20 market was effectively a monopoly held by Roche/Biogen Idec's Rituxan (rituximab), the first-in-class chimeric anti-CD20 antibody driving multi-billion-dollar sales across NHL, CLL, and RA. Ofatumumab — a fully human anti-CD20 mAb binding a distinct membrane-proximal epitope with greater complement-dependent cytotoxicity — was positioned as a differentiated second-generation entrant. The deal preceded the Roche-led validation of obinutuzumab and the BTK-inhibitor revolution (ibrutinib, acalabrutinib) that subsequently reshaped CLL frontline. Arzerra received FDA accelerated approval October 26, 2009 for fludarabine/alemtuzumab-refractory CLL based on 42% response in a 59-patient pivotal trial — the timing that anchored the May 2009 deal-iteration listing. Commercial uptake disappointed: the agreement was restructured June 2010 with GSK taking sole autoimmune responsibility for £90M upfront, Arzerra was withdrawn from the EU in 2019 and Canada in 2017, and ofatumumab's commercial centre of gravity ultimately shifted to Novartis-licensed Kesimpta (subcutaneous) in relapsing multiple sclerosis.